Notice of stabilisation measures
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Notice of stabilisation measures
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Change in number of shares and votes in Alligator Bioscience AB
During November, the number of shares and votes in Alligator Bioscience AB has increased due to the new issue of shares that was made in con ...
Trading of Alligator Bioscience AB on Nasdaq Stockholm commences today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Alligator Bioscience AB publishes prospectus for Initial Public Offering on Nasdaq Stockholm
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Nomination committee appointed in respect of AGM 2017 in Alligator Bioscience AB (Publ)
According to the instruction for Nomination Committee in Alligator Bioscience AB (publ) adopted at the annual general meeting held on 20 Apr ...
Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013
– Janssen assumes responsibility for all future clinical studies Alligator started dosing in the first clinical phase I dose escalatio ...
Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015
Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for tumor-directed immunotherapy. ...